Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenalidomide + dexamethasone + PBSCT
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Cell Therapies, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Lenalidomide + dexamethasone + PBSCT is a combination regimen used primarily for the treatment of multiple myeloma. Lenalidomide is an immunomodulatory agent that works by helping the bone marrow produce normal blood cells and killing abnormal cells in the bone marrow. Dexamethasone is a synthetic corticosteroid with anti-inflammatory and immunosuppressant properties, often used to reduce inflammation and suppress immune responses. Peripheral blood stem cell transplantation (PBSCT), also known as autologous hematopoietic stem cell transplant (auto-HSCT), involves collecting a patient's own stem cells, administering high-dose chemotherapy (often including lenalidomide and dexamethasone), then reinfusing the collected stem cells to restore bone marrow function. This combination is standard in both induction therapy before transplant and as maintenance therapy after transplant for multiple myeloma[1][2][3][4][5][7].
- Other names
- autologous hematopoietic stem cell transplantauto-HSCTperipheral blood stem cell transplantation
02
Targets
CRBN (Cereblon)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on lenalidomide + dexamethasone + PBSCT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenalidomide + dexamethasone + PBSCT.